A Meta-Analytic Review of the Penn Resiliency Program’s Effect on Depressive Symptoms

Steven M. Brunwasser
University of Michigan

Jane E. Gillham
Swarthmore College and University of Pennsylvania

Eric S. Kim
University of Michigan

The purpose of this review was to evaluate whether the Penn Resiliency Program (PRP), a group cognitive–behavioral intervention, is effective in targeting depressive symptoms in youths. We identified 17 controlled evaluations of PRP (N = 2,498) in which depressive symptoms had been measured via an online search of PsycInfo, Medline, ERIC, and ProQuest Dissertations and Theses and by requesting data from PRP researchers. We combined effect sizes (ESs; Glass’s $d$), using random effects models at postintervention and two follow-up assessments (6–8 and 12 months postintervention). PRP participants reported fewer depressive symptoms at postintervention and both follow-up assessments compared with youths receiving no intervention, with ESs ranging from 0.11 to 0.21. Subgroup analyses showed that PRP’s effects were significant at 1 or more follow-up assessments among studies with both targeted and universal approaches, when group leaders were research team members and community providers, among participants with both low and elevated baseline symptoms, and among boys and girls. Limited data showed no evidence that PRP is superior to active control conditions. Preliminary analyses suggested that PRP’s effects on depressive disorders may be smaller than those reported in a larger meta-analysis of depression prevention programs for older adolescents and adults. We found evidence that PRP significantly reduces depressive symptoms through at least 1-year postintervention. Future PRP research should examine whether PRP’s effects on depressive symptoms lead to clinically meaningful benefits for its participants, whether the program is cost-effective, whether CB skills mediate program effects, and whether PRP is effective when delivered under real-world conditions.

Keywords: depression, prevention, adolescents, meta-analysis, Penn Resiliency Program

Supplemental materials: http://dx.doi.org/10.1037/a0017671.supp

Depression is one of the leading causes of disability worldwide (Murray & Lopez, 1997). Adolescence is a key time in the etiology of depression, with rates increasing dramatically from the early to late teen years (Hankin, 2006). As many as 20%–24% of youths have major depressive episodes by age 18 (Lewinsohn, Rhode, & Seeley, 1998). Elevated but subclinical levels of depressive symptoms are also common in adolescence (Roberts, Lewinsohn, & Seeley, 1991) and are associated with considerable impairment as well as increased risk for clinical depression (Gottlib, Lewinsohn, & Seeley, 1995). Widespread prevention efforts targeting adolescents may be our best hope at alleviating the enormous burden of depression on our society.

Researchers and mental health professionals have responded to this need by developing and testing prevention programs (see Sutton, 2007, for a recent review). These programs target a wide range of risk factors, such as pessimistic cognitive styles, interpersonal difficulties, and family conflict. Most depression prevention programs are adapted from established psychotherapies for depression, such as cognitive–behavioral therapy (CBT) and interpersonal therapy (IPT).

In recent years, several research teams have published meta-analytic reviews of depression prevention programs (Cuijpers, van Straten, Smit, Mihalopoulos, & Beekman, 2008; Horowitz & Garber, 2006; Jané-Llopis, Hosman, Jenkins, & Anderson, 2003; Merry, McDowell, Hetrick, Bir, & Muller, 2004; Stice, Shaw, Bolon, Marti, & Rohde, 2009). These reviews have advanced prevention efforts considerably by allowing researchers to take...
stock of the existing literature and by raising important questions and recommendations for future prevention efforts. These meta-analyses indicate that youths who participate in depression prevention programs report lower levels of depressive symptoms than those who receive no intervention (Horowitz & Garber, 2006; Merry et al., 2004; Stice et al., 2009). In addition, participants in depression prevention programs are less likely to develop depressive disorders (Cuijpers et al., 2008).

The Penn Resiliency Program (PRP; Gillham, Reivich, & Jaycox, 2008) is one of the most widely researched depression prevention programs. PRP is a cognitive–behavioral group intervention designed for youths in late childhood and early adolescence (ages 10–14 years). Although typically a school-based program, PRP has been evaluated in other settings, including primary care clinics and juvenile detention centers. For a description of the intervention content, see Gillham, Brunwasser, and Freres (2008). Findings from the initial efficacy study were promising as PRP prevented depressive symptoms through 2 years of follow-up and reduced the risk for clinically relevant symptoms (Gillham, Reivich, Jaycox, & Seligman, 1995). Since that initial study, however, PRP research findings have been inconsistent. The majority of studies evaluating PRP have found beneficial effects on depressive symptoms in either the overall sample or subgroups of participants. But at least four studies found no significant effects (Gillham, Brunwasser, & Freres, 2008). These conflicting results make it difficult to give an overall appraisal of the program’s effectiveness. Few studies have evaluated PRP’s effects on depressive disorders.

A priority for those who undertake future PRP research is to determine whether PRP is likely to benefit youths if delivered on a wide scale, as intended. Large-scale dissemination would require a considerable investment of time, effort, and finances. Such an investment is justified only if the existing data show promise. A meta-analytic review can help researchers make this determination. We know of 17 controlled studies evaluating PRP’s effects on depressive symptoms with more than 2,000 participants in total. If a quantitative review of these studies revealed no effect on depressive symptoms, then it would be imprudent to continue evaluating the program in its current form or to disseminate the program broadly.

A second priority in PRP research is to understand the program’s inconsistent effects. Research identifying the contexts and subgroups in which PRP is most effective could be used to guide future program development and implementation efforts. A meta-analysis can help researchers to identify factors that moderate intervention effects. Detecting moderation, however, requires considerable statistical power as the analyst compares the strength of effects across studies and subgroups of participants (Hedges & Pigott, 2004). Nearly half of the studies in which PRP has been evaluated have had small samples (N < 100), limiting the power of meta-analytic analyses to reveal moderators. Although it is unlikely that analyses comparing effects across subgroups would yield conclusive results at this time, there may be sufficient power to determine whether PRP’s effects are significant within subgroups of interest.

It is plausible that PRP’s inconsistencies are attributable to within- and between-study differences in participant characteristics. Prevention researchers who employ a targeted approach attempt to identify and recruit youths who are at increased risk for depression and, as such, in the greatest need of early intervention. Targeted intervention includes selective studies, in which participants have a known risk factor for the development of a disorder (e.g., parental depression) and indicated studies, in which participants evidence early symptoms of the disorder (e.g., subclinical depressive symptoms). In contrast, in universal studies, all members of a specific population are recruited, regardless of their level of risk. Depression prevention programs targeting at-risk youths have garnered more support than those delivered universally (Horowitz & Garber, 2006; Merry et al., 2004; Stice et al., 2009). PRP is one of the few depression prevention programs that has been evaluated with both targeted and universal approaches. In this review, we examine the magnitude of PRP’s effects in both targeted and universal studies.

In most studies of PRP, researchers have either not examined or not reported moderators of intervention effects. A few studies have found that PRP’s effects on depressive symptoms differ in boys and girls. At least one study (Gillham, Hamilton, Freres, Patton, & Gallop, 2006) found stronger effects for girls than boys, while other studies have found the opposite effect (e.g., Reivich, 1996). Some PRP studies have found that participants’ preintervention levels of depressive symptoms moderated the intervention effects. For example, Gillham and colleagues found that PRP reduced the likelihood of receiving a diagnosis of depression or anxiety in participants with elevated baseline symptoms but not in those with low baseline symptoms (Gillham, Hamilton, et al., 2006). In this review, we evaluate the magnitude of PRP’s effects separately for boys and girls and for participants with elevated and low baseline symptoms.

A second possible source of inconsistency in PRP findings is within- and between-study differences in intervention provider characteristics. In some studies, group leaders were members of the research team (typically psychologists with extensive training in the cognitive-behavioral model, psychology graduate students, or advanced research assistants closely supervised by the program developers). In other studies, group leaders were community providers, who would likely lead intervention groups if PRP were widely disseminated. Unlike research team members, community providers (e.g., school personnel or community mental health providers) typically do not have a direct interest in the research outcome. Gillham and colleagues expressed concern that PRP’s inconsistent findings could be due partly to an attenuation of intervention effects when PRP is evaluated under real-world conditions (i.e., effectiveness trials) as opposed to optimal research conditions (i.e., efficacy trials; Gillham, Brunwasser, & Freres, 2008). A drop-off in intervention effects under real-world conditions would hamper dissemination efforts and limit PRP’s utility. The transportability of interventions is an important concern among depression prevention researchers in general. There is more evidence for preventive effects when group leaders are researchers and highly trained professional interventionists (who are not part of the community setting where programs are delivered) than when group leaders are community providers (Stice et al., 2009). In this review, we evaluate PRP’s effects in studies conducted both by research team leaders and by community providers.

The primary purpose of this meta-analysis was to aggregate data across all controlled studies to determine whether PRP participants have lower levels of depressive symptoms compared with youths who receive no intervention. Additionally, we conducted subgroup analyses to evaluate PRP’s effects in different contexts. We ex-
pected to find more evidence for PRP’s effects among targeted than universal studies and when research team members rather than community providers led intervention groups. We expected PRP’s effects to be significant among both boys and girls and among participants with both low and elevated baseline symptoms. Because we lacked statistical power to detect moderation, we did not focus on analyses in which the strength of PRP’s effects was compared across subgroups. Although limited data were available, we conducted preliminary analyses of PRP’s effects on depressive disorders to determine whether the magnitude of PRP’s effects is comparable to those reported in larger meta-analyses.

Method

Searching

We identified studies for this review using several methods. First, we conducted a search of several online databases: PsychInfo (1990–2009), Medline (1990–2009), ProQuest Dissertations & Theses (1990–2009), and ERIC (1990–2009). Search terms included all known names that have been used to describe PRP (Penn Resiliency Program, Penn Prevention Program, Penn Optimism Program, Penn Program, and Depression Prevention Program) and the names of the lead investigators of the PRP research team (Gillham, Reivich, Jaycox, Shatté, Cardemil, and Seligman). We limited searches so as to retrieve only articles describing empirical studies published no earlier than 1990, the year PRP was developed. The final online search date was February 28, 2009. Second, we cross-referenced the citation lists in each of the articles retrieved via the online search and reviewed the citation lists of existing meta-analyses to ensure we uncovered all PRP studies included in these reviews. Finally, we consulted a database maintained by the program developers since February 2003 in which all research-related requests for the PRP program materials have been recorded. We contacted all researchers who had requested the PRP program materials and asked them to provide data from their studies and to complete a survey asking for details about the study design, participants, group leaders, and intervention delivery.

Selection

Studies included in the review were those in which (a) PRP was compared with a control condition, (b) PRP’s effect on depressive symptoms was evaluated, and (c) data were reported both before the intervention began (baseline) and at one or more postintervention assessment points. No studies were excluded due to suboptimal research methods (e.g., nonrandom assignment); however, we report intervention effects both including and excluding nonrandomized studies. The review included data from both published and unpublished studies.

Steven M. Brunwasser reviewed the abstracts of all articles retrieved via the online database search and obtained the full text for each article that mentioned PRP by name or described a cognitive–behavioral intervention for youths. Both Steven Brunwasser and Jane E. Gillham reviewed the study descriptions provided by the researchers who responded to our request for data to determine whether their studies met inclusion criteria. The final determination of which studies were to be included in the review was made by the consensus of Steven Brunwasser and Jane Gillham.

Data Abstraction

Steven Brunwasser coded all study data into an Microsoft Access (Microsoft Corp., Redmond, WA) database and wrote algorithms to calculate effect sizes (ESs). A trained undergraduate research assistant (Eric S. Kim) served as an independent coder and reentered all data. When data needed to compute ESs were not available in study manuscripts, we contacted the manuscript author(s). In all cases, the authors provided the necessary data to calculate effects on depressive symptoms. We also coded three dichotomous dummy variables representing between-study subgroups of interest: condition assignment (random vs. nonrandom), participant risk status (universal vs. targeted), and group leader type (research team members vs. community providers).

We were also interested in evaluating PRP’s effects across two within-study factors: sex (girls vs. boys) and symptom level (participants with low vs. elevated baseline symptoms). Few PRP studies have reported summary statistics for these subgroups. However, we had access to full data sets for nine studies included in this review, allowing us to calculate ESs by sex and symptom level. A total of 10 studies provided sufficient data to calculate separate ESs for boys and girls, and nine studies provided sufficient data to calculate separate ESs for participants with low and elevated baseline symptoms. We classified participants as having either low or elevated baseline symptoms on the basis of a Children’s Depression Inventory (CDI) cutoff score of 13, a recommended cutoff score (Kovacs, 2001). One study (Roberts, Kane, Thomson, Bishop, & Hart, 2003) reported separate data for participants with low and elevated baseline symptoms on the basis of a CDI cutoff of 15. We chose to include data from this study in the subgroup analyses because the cutoff score was close to the one selected for the other studies.

We then exported the data into the Comprehensive Meta-Analysis Version 2.2.046 software (CMA; Biostat, Englewood, NJ) to conduct analyses. In addition to coding ES data and moderators, we also coded information related to the research design, participant demographics, and intervention delivery for each study. We conducted no formal evaluation of study design quality but have provided detailed information about each study in online supplemental tables.

Effects on Depressive Symptoms

Power analysis. In order to gauge our ability to detect effects on depressive symptoms, we conducted power analyses following the procedures described by Hedges & Pigott (2001). We calculated our power to detect an effect size of 0.20 (\(\alpha = .05\)), an effect that is of a magnitude similar to those reported by recent meta-analytic reviews of depression prevention programs for youths (see Supplemental Table 5).

Calculating effect sizes. We calculated ES estimates (i.e., standardized mean difference scores) for depressive symptoms by dividing the difference in the control group and PRP group means by the standard deviation of the control group (Glass’s \(d\); Glass, McGaw, & Smith, 1981): \(d = (\bar{X}_{\text{Control}} - \bar{X}_{\text{PRP}})/SD_{\text{Control}}\). Positive \(d\) values indicate fewer depressive symptoms in PRP groups com-
pared with control groups. Standardized mean difference scores based on small samples tend to be upwardly biased (Hedges, 1981). We applied Hedges’s (1981) correction to all d estimates to create an unbiased ES estimate: \( d^* = d \times (1 - (3/4d^2 - 1)) \). Hedges’s correction reduces overestimation of the ES in small studies but has a negligible effect on ES estimates in large studies. When the standard deviation in the denominator of the ES is based on 50 degrees of freedom or more, \( d \) and \( d^* \) are nearly identical (Hedges, 1981).

Evaluative studies of PRP have differed in their length of follow-up. We limited analyses to the three most commonly reported assessments (postintervention, 6- to 8-month follow-up, and 12-month follow-up) and calculated separate ESs for each. For studies in which the same outcome variable was measured with more than one instrument, we computed an average ES estimate across the different instruments so that no study provided multiple ESs at a given assessment. When studies had more than one PRP condition (e.g., an adolescent-only PRP group and an adolescent + parent PRP group), we pooled the means and standard deviations of the different PRP conditions in order to calculate one ES. For studies in which PRP was compared with both a no-intervention control condition and an active control condition, we calculated separate ESs comparing PRP with both control conditions.

**Assessing heterogeneity.** We used Q tests at all assessments to determine whether there were any significant violations of homogeneity in the ES distributions. We also evaluated the proportion of heterogeneity between studies using the I² statistic because heterogeneity tests tend to be underpowered (Higgins, Thompson, Deeks, & Altman, 2003).

**Combining effect sizes.** We used random effects models when combining ESs across studies. Fixed effects models assume that between-study differences are due to sampling error alone (Cooper & Hedges, 1994). In contrast, random effects models assume that, in addition to sampling error, there are other sources of between-study variability. Random effects models add a separate variance term \( (v_h) \) to account for nonsampling error. This results in larger ES confidence intervals (Lipsey & Wilson, 2001). The assumptions of random effects models seemed more appropriate for this review, given that there are considerable methodological differences across PRP studies. We followed procedures recommended by Lipsey & Wilson (2001) when calculating mean ESs. The unbiased standardized mean difference score \( (d^*') \) for each study was weighted by its inverse variance \( (\omega) \): \( \omega = 1/(SE^2 + v_h) \), where \( SE \) represents the standard error of the effect size estimate. The weighted ESs were then added and divided by the sum of the inverse variance weights across all studies. This produced a mean ES \( (d_{..}) \) for each assessment.

**Converting ESs.** Although standardized mean difference scores are statistically intuitive, they do not lend themselves readily to clinical interpretation (Acion, Peterson, Temple, & Arndt, 2006). To facilitate comprehension of ESs, we converted standardized mean difference scores into more easily interpretable metrics. First we converted the mean ESs on the CDI from standard deviation units to the CDI’s scoring metric. We did this by multiplying the mean ES for all studies that used the CDI \( (k = 16) \) by the pooled CDI standard deviation across the control groups. This product represents the average benefit of PRP on the CDI metric (Lipsey & Wilson, 2001). A product of 0.50, for example, means that PRP groups scored, on average, half a point lower than the control groups on the CDI.

Second, we converted ESs into estimates of the probability of superiority (PS). The PS score is an estimate of the probability that a randomly selected PRP participant had a favorable outcome (i.e., lower depressive symptoms) compared with a randomly selected control participant. A PS score of 0.50 indicates that there is 50% chance that a randomly selected PRP participant had a better score than a randomly selected control participant (i.e., no intervention effect). Scores ranging from 0.51 to 1.00 indicate preferable outcome for PRP participants, whereas scores from 0.00 to 0.49 indicate a preferable outcome for control participants (Grissom & Kim, 2005). When full data sets were accessible, we calculated PS by dividing the Mann–Whitney U statistic by the product of the sample sizes for the PRP and control conditions: \( PS = U / mn \), where \( m \) represents the sample size for the PRP condition and \( n \) represents the sample size for the control condition. We used an approximate conversion method when there were insufficient data to calculate a U statistic: \( PS = \Phi(d^*/\sqrt{2}) \), where \( \Phi \) is the normal cumulative distribution function. The nonparametric Mann–Whitney U method is preferable because the conversion method assumes that \( d^*/\sqrt{2} \) is based on a comparison of two groups with normally distributed data (Acion et al., 2006); this is an untenable assumption when evaluating depressive symptoms in nonclinical samples.

One can easily convert PS scores into a number-needed-to-treat (NNT) score: \( NNT = 1/(2 \times PS - 1) \). NNT, in this circumstance, represents the approximate number of youths who need to receive PRP, rather than the control condition, to yield one superior outcome. A superior outcome is defined as occurring when a randomly selected PRP participant had a better depressive symptom score than a randomly selected control participant (Kraemer & Kupfer, 2005). We provide PS and NNT scores for each study in Supplemental Table 7.

**Sensitivity analyses.** We conducted several forms of sensitivity analysis to determine whether effects on depressive symptoms were robust. We evaluated the influence of each individual study on the mean ESs with the one-study-removed procedure in CMA. This is an iterative procedure in which mean ESs and confidence intervals of random effects models seemed more appropriate for this review. The distribution of ESs on a funnel plot is normalized through elimination of outlying ESs and imputation of ES estimates for hypothetically missing studies. The mean ES is then recalculated with the imputed studies. If the mean ES remains
significant, one can have increased confidence that missing studies
would not have altered the decision about whether to reject the null
hypothesis (Duval & Tweedie, 2000).

Our inclusion of nonrandomized studies could be another source
of bias. Random assignment to study conditions ensures that
baseline between-group differences are due to chance. Nonran-
domization could add systematic error to ES estimates as differ-
ces at the postintervention data points could reflect baseline
differences rather than intervention effects. To ensure that study
effects were not driven by nonrandomized studies, we performed
all primary outcome analyses again, excluding nonrandomized
studies.

Subgroup and moderator analyses. We used Q tests to eval-
uate whether our subgroup variables (participant risk status, group
leader type, symptom level, and sex) accounted for systematic
variance in PRP’s effects. Q tests are akin to analyses of variance
(ANOVAs) in that they are used to compare within- and between-
group variance (with a chi-square test statistic) to reveal whether
variability between groups exceeds chance expectation (Lipsey &
Wilson, 2001). When evaluating moderators, we used mixed ef-
effects modeling, which assumes that there are both systematic and
nonsystematic sources of heterogeneity in ES estimates (Lipsey &
Wilson, 2001). In mixed effects models, random effects modeling is
used in aggregating ESs within subgroups, and fixed effects
modeling is used in aggregating across subgroups (Overton, 1998).

Effects on Depressive Disorders

As noted, few researchers have evaluated PRP’s effects on
diagnostic outcomes, limiting statistical power to detect effects on
depressive disorders. However, we chose to conduct preliminary
analyses with the available diagnostic data. We wanted to gather
preliminary information about whether PRP’s effects on depres-
sive disorders are of a similar magnitude as those reported in a
larger meta-analysis of depression prevention programs (Cuypers
et al., 2008).

Following the example of Cuypers and colleagues, we evaluated
PRP’s effects on depressive disorders using both relative risk and
relative incidence analyses (Cuypers et al., 2008). Relative risk anal-
yses compare the proportion of participants in each condition who
experience the outcome of interest (i.e., depressive disorders) over the
follow-up period. For each study providing diagnostic data, we cal-
culated risk ratios (RRs) by dividing the PRP group risk (i.e., the
percentage of PRP participants who received a depression diagnosis)
by the control group risk. RRs smaller than 1.00 indicate a beneficia-
effect of PRP, whereas scores greater than 1.00 indicate a benefit for
the control condition. We also calculated the NNT, which represents
the number of participants who would need to receive the interven-
tion in order for one case of depression to be prevented. The NNT is
calculated by taking the inverse of the difference in risk between the
baseline and immediate postintervention assessments, while others
evaluated intervention effects as late as 3 years postintervention.
Most studies included in the review used a targeted (k = 11; n = 1,408)
or did not have a control condition (k = 4). The remaining 22 manuscripts
reported data from 15 separate evaluations of PRP that met our
inclusion criteria (see Supplemental Table 1). We contacted 19
researchers who requested the PRP manuals for research purposes
and received responses from 15. Most of these researchers (n = 9)
indicated that they had not yet conducted evaluations of PRP. Of
the six studies in which PRP was evaluated, four were excluded
either because depressive symptoms had not been assessed (k = 2)
or because there had not been a control condition (k = 2). The
remaining two studies met our inclusion criteria. Thus, a total of 17
evaluations of PRP were included in this review (see Figure 1).

Study Characteristics

A total of 2,498 youths participated in the 17 PRP studies
included in the review. Participants ranged in age from 8 to 18
years old. In most studies, some form of random condition assign-
ment was used (k = 14; n = 2,281) at either the participant,
classroom, or school level. Three studies provided data only at
baseline and immediate postintervention assessments, while others
evaluated intervention effects as late as 3 years postintervention.
Most studies included in the review used a targeted (k = 11; n = 1,408)
or a universal (k = 6; n = 1,090) intervention approach. The number of studies in which the intervention groups
were led by research team members (k = 8; n = 521) was equal
to the number in which the groups were led by community pro-
viders (k = 8; n = 1,884), but the studies with community
providers tended to be much larger. Community providers in-
cluded school staff (i.e., teachers and counselors), learning men-
1046 BRUNWASSER, GILLHAM, AND KIM
In a few studies, school staff led the vast majority of intervention groups, with research team members leading a small number of groups; these studies were coded as having community providers as group leaders. One study (Reivich, 1996) had an equal number of researchers and school staff leading intervention groups and was excluded from subgroup analyses of researchers and community providers.

In four studies, PRP was compared with both a no-intervention control condition and an active control condition. In two of these studies (Gillham, Reivich, Freres, et al., 2007; Reivich, 1996), PRP was compared with the Penn Enhancement Program (PEP), an alternative intervention designed specifically to mimic the “non-cognitive modes of action” (such as adult attention, group cohesion, and the discussion of day-to-day problems and feelings; Reivich, 1996, p. 23) that likely contribute to PRP’s effects. PEP includes psychoeducation and noncognitive skill-building exercises (e.g., techniques for goal setting, communicating, and resisting peer pressure) designed to be relevant to youths with depressive symptoms (Reivich, 1996; Shatté, 1996). In two studies (Pattison & Lynd-Stevenson, 2001; Wass, 2008), PRP was compared with conditions designed to control for social contact and group cohesion (see Supplemental Table 10).

In all but one of the 17 studies included in this review, depressive symptoms were measured with the CDI (Kovacs, 2001). Two studies measured depressive symptoms with both the CDI and the Reynolds Adolescent Depression Scale (Reynolds, 1986). One study measured depressive symptoms with the Depression Self-Rating Scale (Birleson, 1981). Only three studies evaluated PRP’s effects on depressive disorders. Two of these studies assessed for depressive disorders with standardized diagnostic interviews: the Children’s Depression Rating Scale—Revised (Poznanski & Mokros, 1996) and the Diagnostic Interview Schedule for Children, Version IV (Shaffer, Fisher, Lucas, Dulcan, & Schwab-Stone, 2000). Participants completed these interviews at regular intervals during the studies. The third study evaluated PRP’s effects on depressive disorders with computerized medical records from a health maintenance organization (Gillham, Hamilton, et al., 2006).

### Power Analyses

We had a considerable amount of statistical power (from .88 to .98) to detect an effect of 0.20 in our analyses with the overall sample. The power of subgroup analyses to detect an effect of 0.20 was greater than 0.50 except among the subgroup of participants with elevated symptoms and among the subgroup of studies with research team group leaders (see Supplementary Table 5).

---

**Figure 1. Flow of studies included and excluded from the meta-analytic review.**
**Heterogeneity Assessment**

There was no evidence that the amount of variability between study ESs exceeded chance expectation at any assessment, \( \chi^2_{\text{post}}(16) = 21.14, p = .17; \chi^2_{\text{6- to 8-month}}(12) = 12.54, p = .40; \) and \( \chi^2_{\text{post}}(9) = 6.20, p = .72. \) The proportion of heterogeneity between studies was less than 25% (which is considered low) at all assessments, \( I^2_{\text{post}} = 24.30, I^2_{\text{6- to 8-month}} = 4.28, \) and \( I^2_{\text{post}} = 0.00 \) (Higgins et al., 2003; see Supplemental Table 6 for details on heterogeneity analyses).

**Effects on Depressive Symptoms**

The mean ES comparing PRP and no-intervention control conditions at postintervention was significant (i.e., significantly different than 0), \( d_w = 0.11, 95\% CI [0.01, 0.20], \) ESs ranged from −0.61 to 0.59, and PRP groups had fewer depressive symptoms than control groups in 14 of 17 studies. On average, PRP groups scored 0.86 points lower on the CDI (indicating fewer depressive symptoms) than control groups, and PS scores ranged from 0.48 to 0.69. The mean ES remained significant at the two long-term follow-ups. At postintervention, the one-month effect size (unbiased standardized mean difference score).

<table>
<thead>
<tr>
<th>Study label</th>
<th>Postintervention</th>
<th>6- to 8-month follow-up</th>
<th>12-month follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>( \omega )</td>
<td>( d^e )</td>
</tr>
<tr>
<td>Cardenil, 2002</td>
<td>Study 1</td>
<td>46</td>
<td>9.9</td>
</tr>
<tr>
<td></td>
<td>Study 2</td>
<td>109</td>
<td>21.6</td>
</tr>
<tr>
<td>Chaplin, 2006</td>
<td>226</td>
<td>36.6</td>
<td>0.29 [0.03, 0.55]</td>
</tr>
<tr>
<td>Gillham, 1994, Study 2</td>
<td>94</td>
<td>18.6</td>
<td>0.21 [−0.20, 0.62]</td>
</tr>
<tr>
<td></td>
<td>2006a</td>
<td>40</td>
<td>9.1</td>
</tr>
<tr>
<td></td>
<td>2006b</td>
<td>216</td>
<td>35.8</td>
</tr>
<tr>
<td></td>
<td>2007a</td>
<td>427</td>
<td>53.4</td>
</tr>
<tr>
<td></td>
<td>2007b</td>
<td>371</td>
<td>45.6</td>
</tr>
<tr>
<td>Jaycox, 1994</td>
<td>121</td>
<td>23.4</td>
<td>0.30 [−0.06, 0.66]</td>
</tr>
<tr>
<td>MacKenzie, 2008</td>
<td>202</td>
<td>34.2</td>
<td>0.24 [−0.52, 0.04]</td>
</tr>
<tr>
<td>Patterson, 2001</td>
<td>48</td>
<td>10.2</td>
<td>0.08 [−0.50, 0.67]</td>
</tr>
<tr>
<td>Quayle, 2001</td>
<td>42</td>
<td>9.2</td>
<td>−0.61 [−1.23, 0.01]</td>
</tr>
<tr>
<td>Reivich, 1996</td>
<td>93</td>
<td>18.9</td>
<td>0.04 [−0.37, 0.45]</td>
</tr>
<tr>
<td>Roberts, 2003</td>
<td>179</td>
<td>31.5</td>
<td>0.05 [−0.25, 0.34]</td>
</tr>
<tr>
<td>Tellier, 1998</td>
<td>48</td>
<td>10.4</td>
<td>0.39 [−0.19, 0.97]</td>
</tr>
<tr>
<td>Wass, 2008</td>
<td>21</td>
<td>4.8</td>
<td>0.51 [−0.36, 1.38]</td>
</tr>
<tr>
<td>Yu, 2002</td>
<td>215</td>
<td>35.5</td>
<td>0.23 [−0.04, 0.50]</td>
</tr>
</tbody>
</table>

**Note.** Several studies included in this review have multiple manuscripts that report findings from the same study. So for example, Jaycox et al. (1993), Jaycox et al. (1994), Gillham (1994, Study 1), Gillham et al. (1995), and Gillham & Reivich (1999) all report data from the same study. Rather than label each study with the citation from each article providing data for that study, we have provided concise study labels that include the first author’s last name and the year of the first published research manuscript describing that study. In the online supplementary tables we provide a table (Supplemental Table 1) that lists all of the manuscripts for each study label. Readers may refer to this table in order to match manuscripts to studies. \( \omega \) = inverse variance weight; \( d^e \) = effect size (unbiased standardized mean difference score).
vention mean ES became nonsignificant when we adjusted for publication bias using the trim-and-fill procedure, $d_{post} = 0.09, 95\% \text{ CI} [-0.01, 0.19]$, and when we removed studies with a nonrandomized design, $d_{+} = 0.09, 95\% \text{ CI} [-0.02, 0.19]$. Therefore, the postintervention effect, while significant, is precarious and warrants cautious interpretation. In contrast, there was considerable evidence that the long-term follow-up effects were robust. No single study when removed from analyses carried enough weight to nullify the mean ES at either follow-up assessment. Additionally, the mean ESs remained significant after we adjusted for possible publication bias with the trim-and-fill procedure, $d_{+6-12\text{-month}} = 0.17, 95\% \text{ CI} [0.07, 0.28]$, and when we excluded nonrandomized studies, $d_{+6-12\text{-month}} = 0.20, 95\% \text{ CI} [0.09, 0.31]$, and $d_{+12\text{-month}} = 0.18, 95\% \text{ CI} [0.07, 0.31]$.

Subgroup analyses: Between-study factors. This review had limited power to reveal significant moderation, and heterogeneity analyses showed that there was little between-study variation to capture in moderator analyses. None of our hypothesized moderators accounted for a significant amount of heterogeneity in ESs. Therefore, we focused on analyses that evaluated whether PRP’s effects were significant in subgroups of interest. Moderation statistics (between-group $Q$ statistics) are available in Supplemental Table 6.

The mean ES for targeted studies was significant at all three assessments: $d_{+post} = 0.14, 95\% \text{ CI} [0.01, 0.26]; d_{+6- to 8\text{-month}} = 0.23, 95\% \text{ CI} [0.11, 0.36]; d_{+12\text{-month}} = 0.22, 95\% \text{ CI} [0.06, 0.38]$. The mean ES among universal studies was significant at the 12-month follow-up, $d_{+} = 0.19, 95\% \text{ CI} [0.01, 0.37]$, but not at postintervention, $d_{+} = 0.06, 95\% \text{ CI} [-0.10, 0.23]$, or the 6- to 8-month follow-up, $d_{+} = 0.15, 95\% \text{ CI} [-0.02, 0.33]$. The effects among both research team leaders and community providers were not significant at postintervention: $d_{+} = 0.20, 95\% \text{ CI} [-0.02, 0.41]$, and $d_{+} = 0.08, 95\% \text{ CI} [-0.04, 0.19]$, respectively. The mean ESs for both research team and community leaders were significant at the 6- to 8-month assessment, however: $d_{+} = 0.29, 95\% \text{ CI} [0.06, 0.53]$, and $d_{+} = 0.17, 95\% \text{ CI} [0.06, 0.28]$, respectively. The mean ESs for both research team and community leaders remained significant at 12-month follow-up: $d_{+} = 0.31, 95\% \text{ CI} [0.03, 0.60]$, and $d_{+} = 0.18, 95\% \text{ CI} [0.05, 0.32]$, respectively (see Supplemental Table 8).

Subgroup analyses: Within-study factors. PRP’s effects among girls were significant at the 6- to 8-month follow-up, $d_{+} = 0.19, 95\% \text{ CI} [0.02, 0.35]$, but not at postintervention, $d_{+} = 0.06, 95\% \text{ CI} [-0.11, 0.22]$, or the 12-month follow-up, $d_{+} = 0.16, 95\% \text{ CI} [-0.01, 0.32]$. PRP’s effects among boys were significant at both follow-up assessments, $d_{+6- to 8\text{-month}} = 0.21, 95\% \text{ CI} [0.05, 0.37]$, and $d_{+12\text{-month}} = 0.25, 95\% \text{ CI} [0.08, 0.41]$, but were not significant at postintervention, $d_{+} = 0.05, 95\% \text{ CI} [-0.12, 0.22]$. PRP’s effects among low-symptom participants were significant at all assessments: $d_{+post} = 0.13, 95\% \text{ CI} [0.02, 0.24]$. $d_{+6- to 8\text{-month}} = 0.15, 95\% \text{ CI} [0.01, 0.29]$; $d_{+12\text{-month}} = 0.19, 95\% \text{ CI} [0.04, 0.34]$. Effects among participants with elevated symptoms were significant at both follow-up assessments, $d_{+6- to 8\text{-month}} = 0.28, 95\% \text{ CI} [0.03, 0.53]$, and $d_{+12\text{-month}} = 0.27, 95\% \text{ CI} [0.04, 0.51]$, but not at postintervention, $d_{+post} = 0.18, 95\% \text{ CI} [-0.03, 0.39]$ (see Supplemental Table 9).

### Depressive Disorders

The mean IRR comparing PRP and no-intervention control conditions was 0.89, 95\% CI [0.64, 1.24], indicating that PRP participants were approximately 11\% less likely to receive a depression diagnosis. Individual study IRRs ranged from 0.80 to 1.10. The mean RR was 0.90, 95\% CI [0.66, 1.23], indicating a risk reduction of 10\% in the PRP group. Neither of these effects represents a significant benefit of PRP. Overall, 75 of 622 PRP participants (totaling 1,238 PYs) met criteria for a depressive disorder as compared with 68 of 470 control group participants (totaling 920 PYs). The NNT across all three studies was equal to 41 (see Supplemental Table 11).

PRP did not significantly reduce the risk for depressive disorders among any subgroups examined. However, preliminary analyses suggest that boys and participants with elevated symptoms may benefit from PRP more than girls and low-symptom participants. Among boys, the mean IRR was 0.74, 95\% CI [0.45, 1.24], representing a 26\% reduction in incidence in the PRP group, compared with a mean IRR among girls of 1.02, 95\% CI [0.65, 1.59]. PRP participants with elevated symptoms were 16\% less likely to have a diagnosis, IRR$_{E}$ = 0.84, 95\% CI [0.52, 1.36], compared with no-intervention control participants with elevated symptoms, while there was practically no benefit for low-symptom PRP participants, IRR$_{L}$ = 0.94, 95\% CI [0.58, 1.51]. The NNT among boys and participants with elevated symptoms was 23 and 16, respectively, compared with 238 and 65 among girls and low-symptom participants, respectively (see Supplemental Table 12).

### Discussion

**Effects on Depressive Symptoms**

The primary goal of this meta-analysis was to determine whether PRP is effective in targeting depressive symptoms. We found that youths who participate in PRP report reliably lower levels of depressive symptoms through 12 months of follow-up compared with youths who receive no intervention. The effects are modest (ranging from 0.11 to 0.21) but of a similar magnitude to those reported in larger meta-analyses of depression prevention programs (Horowitz & Garber, 2006; Jané-Llopis et al, 2003; Merry et al., 2004; Stice et al., 2009). (Direct comparisons with other depression prevention meta-analyses should be made cautiously given that there are important methodological differences between the studies.) On average, PRP groups scored between 0.86 and 1.75 points lower on the CDI than no-intervention control groups. A single point on the CDI is indicative of a change in the frequency or intensity of a depressive symptom.

It is unclear at this time why PRP’s effects became more robust at the follow-up assessments than at postintervention. We considered the possibility that control participants had an increase in depressive symptoms in the first year following the intervention, creating more room for an effect. To evaluate this possibility, we calculated mean depressive symptom scores at each assessment across all studies using the CDI, weighting each study’s mean symptom score by its sample size. Contrary to expectation, the mean control group CDI score tended to decrease over the follow-up period (from $M = 9.39$ at postintervention to $M = 8.80$ at 12-month follow-up). In seven of the eight studies reporting 12-month data, the control group reported decreases in symptoms
from postintervention to 12-month follow-up. The strengthening of PRP’s effects cannot be attributed to an increase in control group symptoms. We also considered the possibility that studies with small postintervention effects were less likely to collect follow-up data leading to overestimates of mean ESs at follow-up assessments. This seems unlikely given that two of the three studies (Tellier, 1998; Wass, 2008) with only postintervention data available had larger than average effects (0.39 and 0.51, respectively). It is also possible that PRP’s effects truly grow stronger over time. It may take time before students begin applying the program skills in their everyday lives. Future research should focus on the relation between participants’ use of the PRP skills and their depressive symptoms over time.

The limited data available show no evidence that PRP is superior to active control conditions at either postintervention or 6- to 8-month follow-up. The dearth of statistical power in these analyses limits our ability to draw firm conclusions. However, the mean ES was not even in the expected direction at either postintervention or 6- to 8-month follow-up, suggesting that PRP is not superior to active control conditions. In the future, researchers should continue to compare PRP with active control conditions in terms of mental health outcomes and in terms of cost and ease of delivery.

Secondary Analyses

We also conducted moderator and subgroup analyses evaluating whether participant and group leader characteristics influence PRP’s effects. There was no evidence that any subgroup variables accounted for a significant amount of heterogeneity. Our ability to detect moderation was limited due to the relatively small sample of studies (k = 17), many of which were underpowered. However, it is important to note that heterogeneity levels were low (particularly at the follow-up assessments). This could mean that the between-study differences have little impact on PRP’s effects. As PRP research accumulates, meta-analysts should continue to evaluate whether contextual factors moderate PRP’s effects.

Participant characteristics. PRP’s effects tended to be larger (though not significantly) at all three assessments when delivered to targeted samples than when delivered universally. This is not surprising given that there is typically more room for an effect in targeted studies. Consistent with two previous meta-analyses (Horowitz & Garber, 2006; Merry et al., 2004) we found no evidence for PRP’s effectiveness in universal studies at the postintervention or 6- to 8-month follow-up assessments. We did find a significant effect of universal studies on depressive symptoms at the 12-month follow-up (d = 0.19), however. This is consistent with findings from a recent meta-analysis of depression prevention programs in which effects of universally delivered interventions were not significant at postintervention but were significant (though smaller than effects of targeted studies) across the long-term follow-up (Stice et al., 2009). Some prevention researchers have suggested that further research into universal prevention may not be warranted (e.g., Stice et al., 2009). However, given the significant long-term effects of universal depression prevention programs and their potential to reach large numbers of youths, we believe it is important to continue efforts to develop and evaluate such programs.

We found evidence for PRP’s effectiveness among both boys and girls. The mean ES among boys was significant at both follow-up assessments, while the mean ES for girls was only significant at 6- to 8-month follow-up. It is noteworthy that the range in ESs among boys and girls was considerable. In two studies, there were particularly large discrepancies in the effects among boys and girls. The ESs for boys in the Reivich (1996) study were relatively large (ranging from 0.35 to 0.61), while the effects for girls were remarkably poor (ranging from −0.39 to 0.06). Conversely, a different study (Gillham, Hamilton, et al., 2006) yielded consistently positive effects for girls (ranging from 0.21 to 0.34) and poorer effects for boys (ranging from −0.33 to 0.16). These findings suggest that contextual factors (e.g., the intervention setting or group leader characteristics) may influence PRP’s effects on boys and girls differently. For example, it could be that having single-sex PRP groups is beneficial for girls but not so for boys. PRP group leaders have noted in supervision that girls seem more engaged in the intervention and feel more comfortable talking about sensitive issues when the group is predominantly or entirely female. Chaplin and colleagues found that girls in single-sex groups attended more PRP sessions and had lower hopelessness scores than girls in coed groups, although both all-girls and co-ed PRP led to similar improvements in depressive symptoms relative to a no-intervention control (Chaplin et al., 2006). A study in which investigators are evaluating the influence of group characteristics (such as the gender composition of groups) on PRP outcomes is underway.

Group leader characteristics. The mean ESs for studies with research team leaders tended to be larger (although not significantly) than those for studies with community leaders at all three assessments; however, the mean ESs were significant at both follow-ups regardless of group leader type. As more studies of PRP are conducted, it will be important to revisit the question of whether there is a drop-off in intervention effects when community providers lead intervention groups. It is encouraging that PRP’s effects were significant with community leaders as effective dissemination is contingent upon PRP’s success when the program leaders are real-world personnel.

Effects on Depressive Disorders

PRP did not have a significant effect on diagnoses of depression. Given that diagnostic outcomes were measured in only three PRP studies, we did not expect to have enough statistical power to detect a significant intervention effect. PRP participants were only 11% less likely than controls to receive a diagnosis, and 41 participants are needed to prevent one case of depression. Our preliminary analyses suggest there may be diagnostic benefits for boys and participants with elevated symptoms, but there is no evidence of benefit for girls or low-symptom participants.

Very few studies of depression prevention programs for youths have measured effects on depression diagnoses. A recent meta-analysis of depression prevention studies for adolescents and adults found that participants in prevention programs were 23% less likely than controls to be diagnosed with depression and that 21 participants needed to receive the intervention to prevent one case of depression (Cuijpers et al., 2006). PRP’s effects on diagnosis appear to be about half this size. There are several possible explanations for this discrepancy. It is possible that PRP’s effects
on depressive symptoms do not translate into prevention of diagnoses. Alternatively, the discrepancies may reflect differences in participants’ ages. The vast majority of studies in which the prevention of the disorder has been examined have included participants in late adolescence through adulthood when depression rates are high. In contrast, PRP targets younger adolescents, who are far less likely to have clinical depression and who may have more difficulty learning and applying cognitive–behavioral skills. A third possibility is that differences in effects reflect differences in risk status. On average, participants in the PRP studies that examined diagnoses scored 9.9 on the baseline CDI (which is between the 57th and 69th percentile depending on participant age and sex; Kovacs, 2001), while most other studies examining prevention of depressive disorders have selected participants at substantially elevated risk.

**Questions and Recommendations for Future Research**

This meta-analysis indicates that PRP participants have reliably lower levels of depressive symptoms compared with participants who receive no intervention, and these effects endure for at least 12 months after the intervention. However, this review leaves us with more questions than answers. PRP was developed with the intention of widespread implementation, leading to a considerable decrease in the burden of depression. Clearly, this lofty goal is far from accomplished. Future research should address the following questions:

- **Are PRP’s effects meaningful?** The most important objective for future research will be to show that PRP’s effects have practical significance. We propose a broad definition for what constitutes a meaningful intervention effect as one that leads to improvements in the emotional health or functioning of the participants, their family members, and/or peers. There are many ways in which PRP could produce meaningful benefits including, but not limited to, the following: (a) preventing, delaying, or lessening the intensity or duration of future psychological disorders; (b) eliminating or ameliorating the distress and impairment associated with subclinical symptoms of depression, anxiety, or externalizing problems; (c) improving interpersonal relationships with peers and family members; (d) increasing awareness of depression among participants, teachers, and guardians and improving their ability to respond effectively; and (e) improving parental well-being and parenting practices (which is the goal of the parent intervention component).

At this time, it is unclear whether PRP yields these benefits. There is no evidence at this time that PRP satisfies our criterion (a) as effects on depressive disorders were not significant. PRP is closest to meeting criterion (b). PRP has enduring effects on depressive symptoms, but it is unclear whether an average reduction in symptoms by one fifth of a standard deviation translates into practical benefits for youths. PRP’s effects are small by many intervention researchers’ standards (e.g., Weisz, Donenberg, Han, & Weiss, 1995). But the meaningfulness of an effect is not simply a function of its magnitude (Prentice & Miller, 1992). Many widely accepted interventions yield small effects, comparable to PRP’s effects on depressive symptoms (Meyer et al., 2001). The important question is whether PRP’s small effect on depressive symptoms is a mediator of practical benefits for youths (e.g., decreased risk for depressive disorders, improved adaptive functioning, and quality of life). Future PRP studies should include outcome measures that better lend themselves to clinical interpretation.

In the short term, effects among youths with elevated depressive symptoms are likely more meaningful than effects among youths who already have low levels of symptoms. This review suggests that PRP is effective in reducing symptoms among students with elevated baseline symptoms. But PRP is not intended to be a short-term treatment program; rather it is intended to impart lasting skills that will reduce the risk for depression as youths enter late adolescence and early adulthood. Unfortunately, few PRP studies have been able to follow youths into this period of heightened risk. Extending follow-up periods would be difficult due to increased costs and attrition, but doing so would improve researchers’ ability to gauge PRP’s potential benefits. It is noteworthy that although screening instruments can be effective in identifying youths at increased risk for depression, many (and perhaps more) youths who score low on these instruments at a screening or baseline assessment will ultimately develop significant levels of depression (Gillham, 2003). Thus, we feel that in the long term, PRP’s effects among low-symptom youths could be just as meaningful as its effects among participants with elevated symptoms.

It is likely that PRP’s effects extend beyond depression. The program is based on cognitive-behavioral skills that are used in the treatment of a variety of psychological disorders (Butler, Chapman, Forman, & Beck, 2006). Because anxiety and externalizing symptoms have high levels of comorbidity with depression, the PRP program developers included content specifically targeting those disorders. Few PRP studies have evaluated these outcomes, but there is some evidence that PRP can improve anxiety and externalizing symptoms (Gillham, Reivich, et al., 2006; Jaycox, Reivich, Gillham, & Seligman, 1994; Roberts, Kane, Bishop, Matthews, & Thomson, 2004). Research into PRP’s effects on anxiety, behavioral problems, and other outcomes can lead to better estimates of the program’s true impact.

- **Is PRP cost effective?** Demonstrating that the intervention yields meaningful benefits is insufficient justification for PRP’s widespread dissemination; researchers must also show that the program is a good investment of resources. Findings from a recent study support the cost effectiveness of a cognitive-behavioral depression prevention program similar to PRP (Lynch et al., 2005). These findings are encouraging and should prompt similar evaluations of PRP’s cost effectiveness. Researchers should consider the cost effectiveness of PRP in relation to attention–control conditions and alternative interventions.

The cost of PRP’s delivery depends on many factors, including the method of its delivery. There are benefits and drawbacks to both universal and targeted prevention approaches (see Offord, Kraemer, Kazdjin, Jensen, & Harrington, 1998). Targeted interventions, for example, have high costs associated with identifying and recruiting at-risk participants. However, universal prevention requires a greater number of intervention group leaders, which increases compensation and training expenses. PRP researchers should consider the cost-effectiveness of universal and targeted prevention strategies separately. It is important to consider the potentially wide range of benefits listed in the previous section when evaluating PRP’s cost effectiveness. Small improvements in a variety of domains could translate into large overall benefits, subsequently improving cost-effectiveness estimates.
How does PRP work? Uncovering the causal mechanisms responsible for PRP’s effects on depressive symptoms should be a priority for future research. Theoretically, PRP works by improving cognitive style and coping skills. In a number of PRP studies, investigators have taken steps to test this causal model of change with mixed findings. Cognitive style has been studied as a mediator of PRP’s effects on depressive symptoms in at least four PRP studies, three of which found at least partial support for the model (Cardemil, Reivich, & Seligman, 2002; Gillham et al., 1995; Roberts et al., 2004; Yu & Seligman, 2002). In several studies, no significant intervention effects on depressive symptoms or cognitive style were found, precluding mediation analyses. In future meta-analyses, researchers should attempt to test whether the hypothesized mediation model holds across studies. Researchers seldom report the data needed to test mediation in meta-analysis, making this a difficult task.

The limited data available provide no evidence that PRP is superior to active control conditions that do not target cognitive risk factors. This is consistent with findings from a previous review of depression prevention studies (Merry et al., 2004). The simplest explanation for this finding is that PRP’s effects on depressive symptoms are attributable to factors other than its cognitive-behavioral training, like increased attention, expectation of benefit, or group cohesion. It is important, however, to examine the possibility that PRP’s effects are attributable to cognitive-behavioral training and that the active comparison conditions produced comparable effects via other mechanisms. In future studies, investigators should continue evaluating potential mediators of the effects of both PRP and active control conditions. Doing so will advance understanding of why these programs produce benefits (when they indeed do produce benefits). PRP researchers should consider whether active control conditions are effective and less costly alternative interventions.

There is evidence from dismantling studies in the depression treatment literature that the behavioral, not cognitive, components of CBT may be primarily responsible for treatment gains (Jacobson et al., 1996). PRP teaches a variety of behavioral coping and problem-solving skills, but few studies have evaluated the cognitive and behavioral program components separately. Future studies should examine these behavioral skills as potential mediators of PRP’s effects. If behavioral components are the active ingredient, it may be prudent to revise the program, putting greater emphasis on these skills.

Is PRP effective when delivered under real-world conditions? Psychosocial interventions often have stronger effects in university-based research studies than in community settings (Weisz et al., 1995). Our finding that community leaders can deliver PRP effectively is an important step toward effective dissemination. However, this finding alone is not sufficient evidence that PRP can produce effects in community settings. In most studies in which community providers led intervention groups, the PRP intervention developers provided direct training and ongoing supervision to the group leaders. Such training and supervision may not be feasible if the program is widely disseminated. There were too few studies for us to evaluate PRP’s effectiveness when delivered by community leaders who did not receive direct training and supervision from the program developers. More research is needed to determine the type of training required for leaders to deliver PRP effectively. We encourage PRP researchers to carefully document their group leader training procedures so that in future meta-analyses, researchers can evaluate whether training methods influence intervention outcomes. Additionally, more research is needed to determine whether PRP is effective when implemented under real-world conditions (i.e., when incorporated into schools and other community settings).

Limitations

This review had several notable limitations. First, we lacked statistical power to evaluate moderators and diagnostic outcomes reliably. Second, we had insufficient data to examine PRP’s theoretical model of change (i.e., that improvements in cognitive style and coping skills mediate intervention effects on depression-related outcomes). Third, we had insufficient data to evaluate important outcomes of interest, like adaptive functioning. Finally, we used an ES statistic (d) that assumes normality in the distributions of the two groups under comparison (Acion et al., 2006). This ES statistic is commonly used in intervention research, including recent meta-analyses of depression prevention programs (e.g., Horowitz & Garber, 2006). Scores on depression measures are rarely normally distributed in nonclinical samples, however; distributions tend to be positively skewed because many participants have few or no symptoms. This may limit the interpretability of our ES estimates. Although there are ES statistics that make less restrictive assumptions, like PS, the information necessary for their calculation (e.g., a U statistic) is rarely reported in intervention studies.

Conclusion

This review confirms that adolescents who participate in PRP have fewer depressive symptoms than participants in no-intervention control conditions as late as 12 months postintervention. While it is encouraging that PRP has enduring effects on symptoms, average effects are small. The top priority in future PRP research should be to determine whether the intervention has a meaningful impact on the lives of its participants. Researchers should examine whether PRP improves adaptive functioning and quality of life and reduces risk for major mental health problems. PRP aims to provide youths with skills that will help them navigate through adolescence, a time of greatly increased risk, without succumbing to depression and its sequelae. Yet most PRP research has not followed participants past early adolescence. PRP researchers should evaluate intervention effects throughout the adolescent years. Other priorities include identifying mediators and moderators of PRP’s effects and showing that the program is transportable and cost effective.

References

References marked with an asterisk indicate studies included in the meta-analysis.


Received November 2, 2008
Revision received September 8, 2009
Accepted September 9, 2009